Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Biogen, Inc.
(NQ:
BIIB
)
299.39
USD
+9.87 (+3.41%)
Official Closing Price
/ Updated:
7:59 PM EST, Dec 5, 2019
/
Add to My Watchlist
View:
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
Press Releases
Related Stories
Blogs
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Intraday
1 Week
1 Month
3 Month
1 Year
Compare to:
None
S&P 500
Nasdaq
NYSE
AMEX
Russell 2000
Basic Materials
Conglomerates
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities
Volume
5,989,400
Open
291.00
Bid (Size)
297.02 (1)
Ask (Size)
298.98 (3)
Prev. Close
289.52
Today's Range
275.04 - 309.06
52wk Range
215.77 - 344.00
Shares Outstanding
211,007,945
Dividend Yield
N/A
Performance
YTD
-1.74%
-1.74%
1 Month
+2.47%
+2.47%
3 Month
+33.68%
+33.68%
6 Month
+33.45%
+33.45%
1 Year
-8.36%
-8.36%
Top News
More News
Biogen Announces Positive Phase 2 Study Results for Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE)
December 03, 2019
from
GlobeNewswire News Releases
Biogen's CTAD Presentation On Aducanumab Elicits Mixed Response
December 05, 2019
Biogen Inc's(NASDAQ: BIIB) presentation of aducanumab data at the Clinical Trials On Alzheimer's Disease Congress has ...
Read More
category
alzheimer's
,
Trading Ideas
,
Cowen
, and 13 more.
from
Benzinga
More News
Read More
Mike Khouw Highlights Unusual Options Activity In Biogen
December 05, 2019
category
Markets
,
Media
,
Market News
, and 6 more.
from
Benzinga
Biogen stock climbs as investors shrug off analyst skepticism about Alzheimer’s drug
December 05, 2019
category
General
,
BIIB
,
Pharmaceuticals
, and 10 more.
from
MarketWatch
UPDATE 1-Novartis R&D boss says doesn't see big opportunity in oral SMA therapy
December 05, 2019
category
companyNews
from
Reuters: Company News
Biogen to make case to skeptics for its controversial Alzheimer's drug
December 05, 2019
category
companyNews
from
Reuters: Company News
Biogen Stock Popped: Here's What Happened In Its Alzheimer's Update
December 05, 2019
from
Investor's Business Daily
Pharmacy benefits manager Abarca inks discount deal for Amgen's Enbrel
December 03, 2019
category
companyNews
from
Reuters: Company News
Cramer Weighs In On Biogen, Caterpillar And More
December 03, 2019
category
CNBC
,
CAT
,
mad money Lightning Round
, and 10 more.
from
Benzinga
Biogen's Alzheimer's Drug 'Falls Far Short Of Compelling Argument For Approval,' Baird Says In Downgrade
December 02, 2019
category
ESALY
,
Benzinga
,
Biotech
, and 11 more.
from
Benzinga
Astellas’ $3 billion gene therapy deal steadies investors after stalled Roche acquisition
December 03, 2019
category
GILD
,
M&A
,
BOLD
, and 15 more.
from
MarketWatch
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.